Influence of the Molecular Subtype-Dependent Immune Microenvironment of Metastatic Axillary Lymph Nodes on Breast Cancer Patient Outcomes
Our results showed that ALN immune profiles and their influence on disease evolution vary by molecular BC subtype and nodal status, suggesting that accurate ALN immune profiling at diagnosis could provide new insights into the immune BC landscape. These observations require validation in larger, prospective cohorts before they can be reliably used to inform clinical decision-making.
Authors
- Montserrat Llobera
- Joan Francesc García-Fontgivell (ORCID: https://orcid.org/0000-0002-3639-983X)
- Esther Sauras
- Albert Roso-Llorach
- Anna Korzyńska (ORCID: https://orcid.org/0000-0002-6488-4832)
- Meritxell Arenas
- S. Martínez (ORCID: https://orcid.org/0000-0001-6185-2889)
- Marylène Lejeune (ORCID: https://orcid.org/0000-0001-8441-9404)
- Marcial García‐Rojo (ORCID: https://orcid.org/0000-0001-6272-9401)
- José Antonio Izuel
- Laia Adalid Llansa
- Noèlia Gallardo-Borràs
- Alba Fischer-Carles
- Daniel Mata
- Jordi Baucells
- Carlos A Lopez
- Laia Reverté
- Lukasz Roszkowiak
- Ramon Bosch Príncep
- Andrea Gras Navarro
- Junior Gómez
- Gloria Bueno
Institutions
- Universitat Pompeu Fabra (ES)
- Institut de Recerca Biomèdica Catalunya Sud (ES)
- Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
- Hospital Universitario Puerta del Mar (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Hospital Universitari Joan XXIII de Tarragona (ES)
- Hospital Universitari de Tortosa Verge de la Cinta (ES)
- Institute of Biocybernetics and Biomedical Engineering (PL)
- Universitat Rovira i Virgili (ES)
- University of Castilla-La Mancha (ES)
- Polish Academy of Sciences (PL)
Publication Details
- Journal
- Pathobiology
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1159/000550086
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Ministerio de Ciencia e Innovación
- Xarxa de Bancs de Tumors de Catalunya
- Instituto de Salud Carlos III
- European Regional Development Fund
- FP7 People: Marie-Curie Actions